The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The evolving treatment of MF, PV, and ET: aiming for clonal elimination
Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses unanswered questions and the evolving treatment of myelofibrosis (MF), essential thrombocythemia (ET), and polycythemia vera (PV), highlighting the importance of aiming for clonal elimination rather than symptom control. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
